Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:48 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed
NCT02722135 · Boehringer Ingelheim · PHASE1 · withdrawn · last registry update 2017-01-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Boehringer Ingelheim |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PLK1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-12-22Also stopped (withdrawn): Yale University, volasertib + belinostat (NCT02875002)
- 2017-11-22Results posted on the registry: Boehringer Ingelheim, BI 6727, IV infusion (NCT01023958)
- 2017-04-05Also stopped (withdrawn): University of Alberta, Volasertib + Idarubicin (NCT02527174)
- 2016-12-15Also stopped (withdrawn): Northwestern University, Vincristine Sulfate Liposome + Volasertib (NCT02861040)
- 2016-12-01Also stopped (withdrawn): Anne Beaven, MD, Volasertib + Romidepsin (NCT02757248)
- 2016-09-20Results posted on the registry: Boehringer Ingelheim, pemetrexed + pemetrexed (NCT00824408)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision